Derma Sciences (DSCI) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-1.17M
Depreciation of equipment and improvements
Amortization of intangible assets	2.64M
Amortization of deferred financing costs
Loss on debt extinguishment
Provision of bad debts
Allowance for sales adjustments	1.4M
Provision for inventory obsolescence
Loss on disposal of equipment	20.48K
Deferred rent expense
Compensation charge for employee stock options
Compensation charge for restricted stock
Deferred income taxes	-648.41K
Accounts receivable	-335.08K
Inventories	3.88M
Prepaid expenses and other current assets	-45.78K
Other assets
Accounts payable	-876.07K
Accrued expenses and other current liabilities	-4.31M
Long-term liabilities
Net cash provided by (used in) operating activities
Purchase of equipment and improvements	-235.13K
Purchase of intangible asset
Net cash used in investing activities
Net change in bank line of credit
Long-term debt repayments
Net change in restricted cash
Proceeds from sale of common stock, net of issuance costs	2.25M
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents	329.04K
Net increase in cash and cash equivalents	10.16M
Beginning of period	15.81M
End of period	25.97M
Purchase of license rights
Issuance of common stock and warrants	9.2M
Cash paid
Issuance of warrants and stock options for payment of offering costs
Interest

Entities mentioned with DSCI

View All Entities